About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Mazdutide
- Company
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- 10 recruiting
Efficacy results: Not yet reported
10 recruiting studies currently listed on ClinicalTrials.gov.
Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026
Find a Clinical Trial Near Me
See recruiting studies for Mazdutide and check eligibility with the study team.
Trial details
-
Recruiting NCT NCT06143956
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Not yet reported Eli Lilly and Company 1481 participants Est. completion 2028-02 56 sitesOther conditions: Obesity, OverweightView official trial listing → -
Recruiting NCT NCT06519656
Efficacy of Mazdutide for Treating PCOS
Not yet reported, Not yet reported Shanghai Zhongshan Hospital 50 participants Est. completion 2026-06-30 1 site Stand-aloneOther conditions: Polycystic Ovary SyndromeView official trial listing → -
Recruiting NCT NCT06862908
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 141 participants Est. completion 2027-02-11 1 siteHeart failure Other conditions: ObesityView official trial listing → -
Recruiting NCT NCT06931028
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 260 participants Est. completion 2027-06-11 1 siteOther conditions: Sleep Apnea, Obstructive, ObesityView official trial listing → -
Recruiting NCT NCT06937749
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 165 participants Est. completion 2027-07-22 1 siteMASHView official trial listing → -
Recruiting NCT NCT07083154
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
Not yet reported The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 420 participants Est. completion 2029-08-01 8 sites Stand-aloneType 2 diabetes Other conditions: Dementia, Mild, Mild Cognitive ImpairmentView official trial listing → -
Recruiting NCT NCT07255209
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 180 participants Est. completion 2028-10-31 1 siteOther conditions: Adolescents With Obesity or Overweight With Weight-Related ComorbiditiesView official trial listing → -
Recruiting NCT NCT07469800
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 336 participants Est. completion 2027-04-15 1 siteOther conditions: Overweight, Obesity, HypertensiveView official trial listing → -
Recruiting NCT NCT07517042
ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management
Not yet reported Shanghai Zhongshan Hospital 420 participants Est. completion 2028-12 13 sites Stand-aloneOther conditions: Obesity, Weight ControlView official trial listing → -
Recruiting NCT NCT07633639
GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity
Not yet reported China-Japan Friendship Hospital 200 participants Est. completion 2028-05-01 1 site Stand-aloneOther conditions: ObesityView official trial listing → -
Completed NCT NCT02972645
A Study of LY3305677 in Healthy Participants
Not yet reported Eli Lilly and Company 66 participants Est. completion 2017-07-14 1 siteOther conditions: HealthyView official trial listing → -
Completed NCT NCT03325387
A Study of Multiple Doses of LY3305677 in Healthy Participants
Not yet reported Eli Lilly and Company 56 participants Est. completion 2018-08-03 1 siteOther conditions: HealthyView official trial listing → -
Completed NCT NCT03928379
A Study of LY3305677 in Participants With Type 2 Diabetes
Not yet reported Eli Lilly and Company 24 participants Est. completion 2021-07-08 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT04440345
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects
Not yet reported, Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 60 participants Est. completion 2021-08-06 1 siteOther conditions: Overweight or ObesityView official trial listing → -
Completed NCT NCT04466904
Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM
Not yet reported, Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 42 participants Est. completion 2021-05-28 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT04904913
A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 328 participants Est. completion 2023-12-06 1 siteOther conditions: Overweight/ ObesityView official trial listing → -
Completed NCT NCT04965506
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 252 participants Est. completion 2022-06-11 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT05606913
A Study of IBI362 in Participants With Type 2 Diabetes
Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 731 participants Est. completion 2024-04-09 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT05607680
A Study of IBI362 in Participants With Obesity or Overweight
Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 610 participants Est. completion 2024-04-16 23 sitesOther conditions: Obesity Or OverweightView official trial listing → -
Completed NCT NCT05623839
A Study of LY3305677 in Participants With Obesity Or Overweight
Not yet reported Eli Lilly and Company 32 participants Est. completion 2023-06-27 3 sitesOther conditions: Overweight, ObesityView official trial listing → -
Completed NCT NCT05628311
A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 319 participants Est. completion 2024-05-09 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT05793450
Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment
Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 20 participants Est. completion 2023-11-17 1 siteOther conditions: Renal ImpairmentView official trial listing → -
Completed NCT NCT05815680
A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects
Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 48 participants Est. completion 2023-10-30 1 siteOther conditions: Overweight Subjects, Obese SubjectsView official trial listing → -
Completed NCT NCT06124807
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
Not yet reported Eli Lilly and Company 179 participants Est. completion 2025-07-09 29 sites Stand-aloneOther conditions: Obesity, Overweight and ObesityView official trial listing → -
Status unknown NCT NCT06164873
A Study of IBI362 9 mg in Chinese Adults With Obesity
Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 462 participants Est. completion 2025-09-19 1 siteOther conditions: ObesityView official trial listing → -
Completed NCT NCT06184568
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 349 participants Est. completion 2026-02-09 1 siteType 2 diabetes Other conditions: ObesityView official trial listing → -
Completed NCT NCT06536023
This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity
Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 36 participants Est. completion 2025-08-01 1 siteOther conditions: Adolescents With ObesityView official trial listing → -
Completed NCT NCT06817356
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Not yet reported Eli Lilly and Company 308 participants Est. completion 2026-05-19 25 sites Stand-aloneAlcohol use disorderView official trial listing → -
Active, not recruiting NCT NCT06884293
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 479 participants Est. completion 2027-06-30 1 siteOther conditions: Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)View official trial listing → -
Active, not recruiting NCT NCT07000955
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
Not yet reported, Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 98 participants Est. completion 2027-05-14 1 siteOther conditions: ObesityView official trial listing → -
Not yet recruiting NCT NCT07135141
Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity
Not yet reported Beijing Friendship Hospital 256 participants Est. completion 2029-09-30 14 sites Stand-aloneOther conditions: Severe ObesityView official trial listing → -
Not yet recruiting NCT NCT07417306
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 912 participants Est. completion 2027-12-31 1 siteType 2 diabetesView official trial listing → -
Not yet recruiting NCT NCT07654062
Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)
Not yet reported Shandong Provincial Hospital 150 participants Est. completion 2029-07 1 site Stand-alonePrediabetesView official trial listing → -
Not yet recruiting NCT NCT07657676
Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
Not yet reported China National Center for Cardiovascular Diseases 116 participants Est. completion 2027-12-31 1 site Stand-aloneOther conditions: Obesity & Overweight, Coronary Heart DiseaseView official trial listing → -
Not yet recruiting NCT NCT07713992
Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide
Not yet reported Tianjin Medical University 72 participants Est. completion 2028-02-01 Stand-aloneType 2 diabetesMASLDView official trial listing → -
Not yet recruiting NCT NCT07718126
Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
Not yet reported, Not yet reported West China Hospital 60 participants Est. completion 2028-08-31 3 sites Stand-aloneMASH Other conditions: Hepatic Steatosis, Living Liver DonorsView official trial listing → -
Not yet recruiting NCT NCT07767552
Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial
Not yet reported Yanbing Li 249 participants Est. completion 2029-06-30 1 site Stand-aloneType 2 diabetesView official trial listing → -
Not yet recruiting NCT NCT07775846
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy
Not yet reported Huijie Zhang 820 participants Est. completion 2029-06-30 1 site Stand-aloneChronic kidney diseaseView official trial listing → -
Not yet recruiting NCT NCT07781150
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer
Not yet reported Tongji Hospital 128 participants Est. completion 2031-06-30 6 sites Stand-aloneOther conditions: Obesity, Overweight, Atypical Endometrial Hyperplasia, Endometrial Carcinoma Stage I, Endometrioid Endometrial CancerView official trial listing → -
Not yet recruiting NCT NCT07797101
Body-weight Reduction Effect on Portal Hypertension in Compensated Cirrhosis
Not yet reported The Second Affiliated Hospital of Chongqing Medical University 50 participants Est. completion 2029-05-31 Stand-aloneOther conditions: Cirrhosis, Portal Hypertension, Fatty Liver Disease, GLP-1View official trial listing → -
Not yet recruiting NCT NCT07803705
Efficacy of Mazdutide on Fatty Pancreas
Not yet reported Tongji Hospital 194 participants Est. completion 2028-12-30 1 site Stand-aloneOther conditions: Fatty Pancreas, Overweight, ObesityView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Related On The Pen coverage
The Weekly Dose & livestreams
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.